Validation of COVID-19 serologic tests and large scale screening of asymptomatic healthcare workers
AuthorMullins, Kristin E
Harris, Anthony D
MetadataShow full item record
AbstractObjectives: Serologic testing for SARS-CoV-2 is an important element in the fight to slow the COVID-19 pandemic. This study aimed to validate two serologic tests for total (IgM, IgG, IgA) SARS-CoV-2 antibodies, (i) the Ortho-Clinical Diagnostics Anti-SARS-CoV-2 Total Antibody assay for the Vitros 5600 analyzers and (ii) a manual laboratory developed ELISA (FDA EUA pending), for use in parallel orthogonal testing of asymptomatic healthcare workers and affiliates of the University of Maryland Medical System. Design and Methods: Validation and verification of the two tests was performed using samples from hospitalized patients that were found to be PCR positive for SARS-CoV-2, samples pre-COVID-19, and samples from individuals with current/previous infections with other viruses. Healthcare workers and affiliates from across the University of Maryland Health System were provided testing free of charge and their results were reported as reactive or non-reactive if the two tests were concordance, or indeterminate if the results were discordant. Results: Validation testing found the Ortho Vitros test to be 100% (73/73) sensitive, and 99.3% (152/153) specific, while the UMMC ELISA was found to be 97.6% (204/209) sensitive and 100% (288/288) specific. Real world testing among 8399 healthcare workers found that 2.9% (247/8399) of healthcare workers were positive for anti- SARS-CoV-2 antibodies by both tests. An indeterminate rate of 1.1% (91/8399), in which one test reported reactive results, and one as non-reactive was also seen. Conclusions: Parallel orthogonal testing improves the positive and negative predictive value of serologic testing in populations with low prevalence. The use of an indeterminate result from parallel orthogonal testing allows for the follow-up and re-testing, which helps resolve discrepancies between assays.
Rights/TermsCopyright © 2021 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/14517
- Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients.
- Authors: Chansaenroj J, Yorsaeng R, Posuwan N, Puenpa J, Sudhinaraset N, Chirathaworn C, Poovorawan Y
- Issue date: 2021 Mar 9
- Closing the serological gap in the diagnostic testing for COVID-19: The value of anti-SARS-CoV-2 IgA antibodies.
- Authors: Infantino M, Manfredi M, Grossi V, Lari B, Fabbri S, Benucci M, Fortini A, Damiani A, Mobilia EM, Panciroli M, Pancani S, Pesce G
- Issue date: 2021 Mar
- SARS-CoV-2 Seroprevalence in Healthcare Workers of Kaunas Hospitals during the First Wave of the COVID-19 Pandemic.
- Authors: Pereckaitė L, Dambrauskienė A, Urbonienė D, Sadauskas S, Petrikonis K, Naudžiūnas A, Vitkauskienė A
- Issue date: 2021 Feb 6
- Anti-SARS-CoV-2 IgM improves clinical sensitivity early in disease course.
- Authors: Higgins V, Fabros A, Wang XY, Bhandari M, Daghfal DJ, Kulasingam V
- Issue date: 2021 Apr
- Initial determination of COVID-19 seroprevalence among outpatients and healthcare workers in Minnesota using a novel SARS-CoV-2 total antibody ELISA.
- Authors: Thomas SN, Altawallbeh G, Zaun CP, Pape KA, Peters JM, Titcombe PJ, Dileepan T, Rapp MJ, Bold TD, Schacker TW, Arbefeville S, Ferrieri P, Thyagarajan B, Jenkins MK, Karger AB
- Issue date: 2021 Apr